| domain | evidence-based finding | suggested ontology terms | evidence strength/limitations |
|---|---|---|---|
| Disease name/definition | BPTF-related neurodevelopmental disorder is also called neurodevelopmental disorder with dysmorphic facies and distal limb anomalies (NEDDFL); core syndrome includes developmental delay/intellectual disability, speech delay, postnatal microcephaly, and dysmorphic features due to heterozygous BPTF variants (pqac-00000000, pqac-00000002, pqac-00000011) | OMIM:617755; MONDO: not verified/uncertain; disease label: NEDDFL | Strong human cohort evidence from 2017 and 2021; MONDO/Orphanet identifier not verified in available evidence |
| Synonyms | BPTF-related neurodevelopmental disorder; NEDDFL; neurodevelopmental disorder with dysmorphic facies and distal limb anomalies (pqac-00000000, pqac-00000003) | Exact synonym mapping pending external ontology verification | Strong for naming in literature; formal synonym list incomplete in available context |
| Evidence source type | Data are aggregated from published human case series/cohorts and model-organism studies, not EHR-derived datasets in the available evidence (pqac-00000002, pqac-00000003) | ECO:0000218 expert assertion supported by traceable author statement (suggested) | Strong for published-source provenance; no registry-scale natural history dataset identified |
| Causal gene/locus | Causal gene is BPTF on chromosome 17q24.2; disease is associated with heterozygous pathogenic variants and haploinsufficiency (pqac-00000002, pqac-00000010) | HGNC:BPTF; UBERON not applicable; Sequence Ontology terms: frameshift_variant, stop_gained, splice_acceptor_variant/splice_donor_variant, inframe_deletion, missense_variant | Strong for gene-disease validity; exact HGNC ID not provided in available context |
| Protein/complex | BPTF is the largest subunit of the nucleosome remodeling factor (NURF) chromatin-remodeling complex (pqac-00000000, pqac-00000003) | GO:0006338 chromatin remodeling; GO:0030674 protein-containing complex (general); NURF complex term suggested if curated externally | Strong mechanistic consensus; exact GO complex accession for NURF not verified here |
| Molecular mechanism | Current best-supported mechanism is BPTF haploinsufficiency causing dysregulated chromatin remodeling and transcription during neurodevelopment (pqac-00000000, pqac-00000001, pqac-00000002, pqac-00000003) | HP:0000006 Autosomal dominant inheritance; GO:0006357 regulation of transcription by RNA polymerase II; GO:0006338 chromatin remodeling | Strong for loss-of-function/haploinsufficiency; no evidence for protective variants or environmental triggers |
| Chromatin-reader biology | BPTF binds H3K4me3 through its PHD finger and H4K16ac through its bromodomain, supporting an epigenetic reader/remodeler role (pqac-00000000) | GO:0042393 histone binding; GO:0016568 chromatin modification (broad); CHEBI terms for modified histones could be added in curation | Moderate-strong mechanistic evidence; largely inferred from molecular studies summarized in clinical paper |
| Core phenotype: developmental delay/intellectual disability | Reported in 10/10 individuals in the 2017 cohort and 88% in the 2021 cohort (pqac-00000002, pqac-00000001, pqac-00000009) | HP:0001263 Global developmental delay; HP:0001249 Intellectual disability | Strong replicated cohort evidence; severity spectrum incompletely quantified |
| Core phenotype: speech delay | Reported in 10/10 individuals in 2017 and 85% in 2021 (pqac-00000002, pqac-00000001, pqac-00000009) | HP:0000750 Delayed speech and language development | Strong replicated cohort evidence |
| Core phenotype: postnatal microcephaly | Reported in 7/9 individuals in 2017; 42% in 2021 cohort summary; 60% microcephaly at assessment in one detailed 2021 extraction; 40% had microcephaly at birth in that extraction (pqac-00000002, pqac-00000001, pqac-00000004, pqac-00000008) | HP:0000252 Microcephaly; HP:0000253 Progressive microcephaly (suggested where postnatal worsening documented) | Strong that microcephaly is common; exact frequency varies with denominator/definition across summaries |
| Core phenotype: dysmorphic features | Dysmorphic features were present in 9/10 in 2017 and 77% in one 2021 summary; all 20 individuals with available detailed dysmorphology data reportedly had mild dysmorphic features in another 2021 extraction (pqac-00000002, pqac-00000001, pqac-00000004, pqac-00000008) | HP:0001999 Facial dysmorphism; phenotype-specific HPOs may include pointed chin, bulbous nose, prominent nasal ridge | Strong that dysmorphism is common; exact aggregate frequency varies by denominator and ascertainment |
| Core phenotype: motor delay | Motor delay reported in 69% of 2021 cohort (pqac-00000001, pqac-00000009) | HP:0001270 Motor delay | Moderate-strong; not explicitly quantified in 2017 extraction |
| Core phenotype: hypotonia | Hypotonia/history of hypotonia reported in 38% of 2021 cohort (pqac-00000001, pqac-00000004, pqac-00000008) | HP:0001252 Hypotonia | Moderate-strong cohort evidence |
| Additional neurologic phenotype: seizures/EEG abnormalities | Seizures/EEG abnormalities were newly emphasized in 2021; 6 patients had seizure history requiring treatment, and 2 had electrographic abnormalities only (pqac-00000004, pqac-00000008, pqac-00000011) | HP:0001250 Seizure; HP:0010843 Abnormality of the EEG | Moderate evidence from expanded cohort; 2024 epilepsy-focused paper identified bibliographically but not available in accessible full text |
| Neuroimaging | In 2021, MRI was normal in 8/13 imaged individuals and mildly abnormal in 5/13, indicating variable and often subtle brain structural findings (pqac-00000004, pqac-00000008, pqac-00000011) | HP:0410263 Abnormal brain MRI; UBERON:0000955 brain | Moderate evidence; exact MRI anomaly types not fully extractable from available context |
| Skeletal/limb phenotype | Distal limb anomalies are part of the syndrome label; reported findings include scoliosis, cutaneous syndactyly, sandal-gap anomalies, limb-length discrepancy, and delayed bone age in some individuals (pqac-00000007, pqac-00000011) | HP:0001159 Syndactyly; HP:0002650 Scoliosis; HP:0010687 Abnormality of the digits | Moderate evidence; frequencies not fully extractable |
| Ophthalmologic phenotype | Ophthalmologic complications were reported in the expanded 2021 cohort (pqac-00000000, pqac-00000011) | HP:0000478 Abnormality of the eye | Moderate evidence; exact eye findings and frequencies not fully extractable |
| Growth phenotype | Short stature occurred in 25%, decreased weight in 53%, and microcephaly/growth restriction were also observed in 2021 extraction (pqac-00000004, pqac-00000008) | HP:0004322 Short stature; HP:0004325 Poor weight gain | Moderate evidence; 2023 growth-hormone report was identified bibliographically but direct outcome details were unavailable |
| Age at onset/course | Typical onset is congenital/early childhood with neurodevelopmental manifestations recognized in infancy or childhood; published ages ranged from 2.1-13 years in 2017 and 23 months-55 years in 2021, supporting lifelong persistence (pqac-00000002, pqac-00000009) | HP:0003577 Congenital onset; HP:0011463 Childhood onset | Strong for pediatric onset and chronic course; no formal staging system identified |
| Variant spectrum | 2017: 8 loss-of-function and 2 missense variants among 10 unrelated individuals. 2021: 20 distinct variants including 9 frameshift, 4 nonsense, 3 splicing, 2 in-frame deletions, 1 missense, and 1 single-exon deletion; ACMG classes included pathogenic, likely pathogenic, and 2 VUS (pqac-00000002, pqac-00000001, pqac-00000009) | Sequence Ontology: frameshift_variant, stop_gained, splice_region/splice_donor/splice_acceptor, inframe_deletion, missense_variant, exon_loss_variant | Strong for predominance of truncating variants; exact HGVS list incomplete in accessible evidence |
| Inheritance | Predominantly autosomal dominant. Initial reports were mostly de novo; 2021 provided first non-mosaic affected-parent transmissions, showing inherited causative variants also occur (pqac-00000001, pqac-00000009, pqac-00000010) | HP:0000006 Autosomal dominant inheritance; HP:0025352 De novo mutation (suggested annotation at variant level) | Strong for AD inheritance with variable expressivity; penetrance not quantified |
| Penetrance/expressivity | Expressivity appears variable, with milder phenotypes noted especially for some missense/inherited cases; penetrance remains not established from available data (pqac-00000005, pqac-00000009) | HP:0003828 Variable expressivity | Moderate evidence for variability; penetrance unknown |
| Population/epidemiology | No reliable prevalence or incidence estimates were identified in the available evidence; published literature consists of rare case series/families (pqac-00000002, pqac-00000009) | Orphan disease; MONDO/Orphanet prevalence pending verification | Major evidence gap |
| Sex distribution | 2021 cohort included 14 males and 11 females in the extracted summary, arguing against a strong sex-limited pattern (pqac-00000009) | PATO sex terms not necessary | Moderate evidence; one extracted count sums to 25 despite cohort described as 26, indicating source-summary inconsistency |
| Diagnostics: clinical | Diagnosis is suspected from syndromic NDD with speech delay, microcephaly, dysmorphic facies, and distal limb anomalies, with supportive MRI/EEG findings when present (pqac-00000000, pqac-00000004, pqac-00000010) | HPO set above; NCIT:C159866 Genetic Testing (broad suggested term) | Strong for phenotype-guided suspicion; no formal consensus clinical criteria identified |
| Diagnostics: genetic testing | WES and chromosomal microarray were used in the landmark cohort; later cohorts identified sequence variants and single-exon deletions, supporting exome/genome sequencing plus CNV analysis as useful approaches (pqac-00000010, pqac-00000008) | NCIT:C101294 Whole Exome Sequencing; NCIT:C63420 Comparative Genomic Hybridization/array-based CNV analysis (suggested broad mapping) | Strong practical evidence from case ascertainment; no disease-specific testing guideline located |
| Functional/omics diagnostics | 2021 authors noted lack of well-validated functional assays and suggested RNA-seq or proteomics may have diagnostic utility for difficult variants such as missense changes (pqac-00000005) | NCIT:C153191 RNA Sequencing; NCIT:C20085 Proteomic Profiling (suggested) | Hypothesis-level/author opinion rather than established clinical standard |
| Differential diagnosis | Differential includes other syndromic neurodevelopmental disorders/chromatinopathies and cases initially labeled as other growth syndromes; one cited 2019 adult case had initially been diagnosed with Silver-Russell syndrome (pqac-00000006) | Broad category: chromatinopathy | Limited direct evidence in available context |
| Treatment/supportive care | No disease-modifying therapy is established. Reported management is supportive and symptom-directed: developmental therapies, educational support, seizure management, and routine multidisciplinary surveillance (inferred from seizure treatments and chronic NDD features) (pqac-00000004, pqac-00000008) | NCIT:C15604 Supportive Care; NCIT:C21072 Physical Therapy; NCIT:C17733 Occupational Therapy; NCIT:C12453 Speech Therapy | Moderate evidence for supportive approach; formal treatment algorithms absent |
| Seizure treatment examples | Reported anti-seizure interventions in 2021 cohort included sodium valproate, levetiracetam, and vagal nerve stimulator use in individual patients (pqac-00000004, pqac-00000008) | NCIT:C29511 Sodium Valproate; NCIT:C1570 Levetiracetam; NCIT:C99939 Vagus Nerve Stimulation | Case-level evidence only; no response rates or syndrome-specific efficacy data |
| Growth hormone | A 2023 report on growth hormone treatment in children with novel BPTF variants was identified bibliographically but not accessible in full text here, so efficacy/safety cannot be reliably summarized (from search history noted in conversation) | NCIT:C1772 Somatropin/Growth Hormone (if later curated) | Explicit evidence gap in accessible corpus |
| Prognosis/outcomes | Available evidence suggests a chronic lifelong neurodevelopmental disorder with survival into adulthood documented (age up to 55 years in 2021 cohort), but no formal survival, mortality, or quality-of-life statistics were identified (pqac-00000009) | ICF/quality-of-life terms could be added later | Major gap: no natural-history or mortality study found |
| Environmental factors | No established environmental, infectious, lifestyle, or protective factors were identified; disease is currently understood as primarily Mendelian/genetic (pqac-00000002, pqac-00000003) | Not established | Strong negative statement based on absence in current literature context |
| Gene-environment interaction | No BPTF-specific gene-environment interaction data were identified (pqac-00000002, pqac-00000003) | Not established | Evidence gap |
| Primary anatomy | Central nervous system/brain, especially forebrain and cerebral cortex, are the primary affected structures based on human phenotype and mouse modeling (pqac-00000003) | UBERON:0000955 brain; UBERON:0001890 cerebral cortex; UBERON:0001891 telencephalon/forebrain suggested | Strong convergent human/model evidence |
| Cell types implicated | Neural progenitor cells and cortical neurons are implicated; mouse data show prolonged progenitor cell cycle, reduced neuronal output, and impaired deep-layer neuron maturation including Ctip2+ neurons (pqac-00000003) | CL:0011115 neural progenitor cell (suggested); CL:0000540 neuron; CL:cortical neuron/deep-layer cortical projection neuron suggested | Strong model evidence; exact CL IDs for all cortical subtypes should be curator-verified |
| Cellular processes | Upstream defect involves impaired chromatin remodeling/transcriptional regulation; downstream effects include prolonged progenitor cell cycle, apoptosis, disrupted neuronal fate specification, cortical lamination defects, and reduced neuronal maturation (pqac-00000003) | GO:0006338 chromatin remodeling; GO:0051301 cell division; GO:0006915 apoptotic process; GO:0022008 neurogenesis; GO:0007417 central nervous system development; GO:0007399 nervous system development | Strong mouse mechanistic evidence; direct human tissue confirmation lacking |
| Subcellular localization | Disease mechanism is centered in the nucleus/chromatin compartment, consistent with a chromatin-remodeling transcription factor (pqac-00000000, pqac-00000003) | GO:0005634 nucleus; GO:0000785 chromatin | Strong general mechanistic inference |
| Molecular profiling | Mouse forebrain RNA-seq identified altered expression of fate-determining transcription factors and pathways related to neural development, apoptotic signaling, and amino acid biosynthesis; dysregulated genes were enriched for Myc binding sites (pqac-00000003) | GO:0009880 embryonic pattern specification; GO:0043066 negative regulation of apoptotic process/related apoptosis terms; GO:0008652 cellular amino acid biosynthetic process | Strong model evidence; no human transcriptomic signature established |
| Expert mechanistic interpretation | Available studies support a causal chain from BPTF loss-of-function to NURF dysfunction, altered chromatin accessibility/transcription in developing cortex, reduced progenitor fitness and neuronal specification, then microcephaly/intellectual disability/speech delay (pqac-00000000, pqac-00000003) | Pathway annotation can center on chromatin remodeling and corticogenesis | Strong synthesis from human genetics plus mouse model |
| Animal model: zebrafish | CRISPR/Cas9 F0 zebrafish bptf disruption caused reduced head size, increased apoptosis, altered proliferation, and abnormal craniofacial patterning (pqac-00000002, pqac-00000010) | NCBITaxon:7955 Danio rerio | Strong experimental support for developmental role; F0 mosaic model limitations |
| Animal model: mouse | Forebrain-specific Bptf conditional knockout mice were viable to adulthood but smaller and showed severe cortical hypoplasia, prolonged progenitor cell cycle, high cell death, disrupted cortical lamination, reduced deep-layer neurons, and neuronal maturation defects (pqac-00000003) | NCBITaxon:10090 Mus musculus | Strong disease-relevant mechanistic model; conditional knockout is more severe than human heterozygous state |
| Natural disease in other species | No naturally occurring veterinary BPTF-related disorder was identified in available evidence (pqac-00000002, pqac-00000003) | Not established | Evidence gap |
| Clinical trials | No disease-specific interventional clinical trials were identified in the available search results (clinical trial search in conversation) | Not established | Evidence gap |
| Prevention/genetic counseling | Prevention is limited to reproductive/genetic counseling, with recurrence risk depending on whether a variant is de novo or inherited from an affected parent; cascade testing may be relevant once a familial variant is known (pqac-00000001, pqac-00000009) | NCIT:C15280 Genetic Counseling | Moderate evidence from inheritance data; no formal counseling guideline identified |
| Unknown/not established fields | Prevalence, incidence, penetrance, founder effects, carrier frequency, environmental modifiers, protective factors, standardized diagnostic criteria, prognostic biomarkers, disease-specific QoL measures, and targeted molecular therapies are not established in the available evidence (pqac-00000002, pqac-00000005, pqac-00000009) | Mark as unknown/not established in KB | Important to preserve as explicit negatives/gaps rather than infer unsupported claims |


*Table: This table summarizes knowledge-base-ready findings for BPTF-related neurodevelopmental disorder/NEDDFL, including core phenotypes, mechanism, diagnostics, inheritance, and model evidence. It also flags important unknowns and limitations where the available evidence is sparse or unverified.*